Blar i St. Olavs hospital på tidsskrift "Journal of Cachexia, Sarcopenia and Muscle"

Viser treff 1-10 av 10

    • Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series 

      Vagnildhaug, Ola Magne; Balstad, Trude Rakel; Ottestad, Inger; Bye, Asta; Greil, Christine; Arends, Jann; Baracos, Vickie; Brown, Leo R.; Dajani, Olav; Dolan, Ross D.; Fallon, Marie; Fraser, Eilidh; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Kaasa, Stein; McDonald, James; Philips, Iain; Sayers, Judith; Simpson, Melanie Rae; Sousa, Mariana S.; Skipworth, Richard J.E.; Laird, Barry J.A.; Solheim, Tora S (Journal article; Peer reviewed, 2024)
      There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and ...

    • Associations between muscle measures, survival and toxicity in patients with limited disease small cell lung cancer receiving concurrent chemoradiotherapy 

      Halvorsen, Tarje Onsøien; Valan, Christine Damgaard; Jordhøy, Marit Slaaen; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)
      Background Standard treatment for patients with limited stage small cell lung cancer (LS SCLC) is concurrent platinum– etoposide chemotherapy and thoracic radiotherapy (TRT). Up to 30% of patients are cured, but severe ...

    • Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients 

      Grønberg, Bjørn Henning; Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Sjøblom, Bjørg; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2019)
      Introduction Several studies show that low skeletal muscle index (SMI) and low skeletal muscle density (SMD) are negative prognostic factors and associated with more toxicity from systemic therapy in cancer patients. ...

    • Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia 

      Pettersen, Kristine; Andersen, Sonja Benedikte; van der Veen, Anna; Nonstad, Unni; Hatakeyema, Shinji; Lambert, Christian; Lach-Trifilieff, Estelle; Moestue, Siver Andreas; Kim, Jana; Grønberg, Bjørn Henning; Schilb, Alain; Jacobi, Carsten; Bjørkøy, Geir (Journal article; Peer reviewed, 2019)
      Background The majority of patients with advanced cancer develop cachexia, a weight loss syndrome that severely reduces quality of life and limits survival. Our understanding of the underlying mechanisms that cause the ...

    • Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series 

      Yule, Michael S.; Thompson, Joshua; Leesahatsawat, Khachonphat; Sousa, Mariana S.; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Dajani, Olav; Fallon, Marie; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; McDonald, James; McGovern, Josh; Roeland, Eric J.; Sayers, Judith; Skipworth, Richard J.E.; Ottestad, Inger; Philips, Iain; Simpson, Melanie Rae; Solheim, Tora S; Vagnildhaug, Ola Magne; McMillan, Donald; Laird, Barry J; Dolan, Ross D. (Journal article; Peer reviewed, 2024)
      Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement ...

    • Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series 

      Brown, Leo R.; Sousa, Mariana S.; Yule, Michael S.; Baracos, Vickie E.; McMillan, Donald C.; Arends, Jann; Balstad, Trude Rakel; Bye, Asta; Dajani, Olav; Dolan, Ross D.; Fallon, Marie T.; Greil, Christine; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Maddocks, Matthew; McDonald, James; Ottestad, Inger; Phillips, Iain; Sayers, Judith; Simpson, Melanie Rae; Vagnildhaug, Ola Magne; Solheim, Tora S; Laird, Barry J; Skipworth, Richard J.E. (Journal article; Peer reviewed, 2024)
      Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most ...

    • Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis. 

      Martins, Lisa; Muscaritoli, Maurizio; Bourdel-Marchasson, I; Kubrac, C; Laird, Barry J.; Gagnon, B; Chasen, Martin; Gioulbasanis, Ioannis; Wallengren, Ola; Voss, A.C.; Goldwasser, F; Jagoe, T; Deans, Chris; Bozzetti, F; Strasser, Florian; Thoresen, Lene; Kazemi, S; Baracos, V. Elaine; Senesse, Pierre (Peer reviewed; Journal article, 2021)
      Background - Cancer-associated weight loss (WL) associates with increased mortality. International consensus suggests that WL is driven by a variable combination of reduced food intake and/or altered metabolism, the latter ...

    • Is there a genetic cause of appetite loss? - An explorative study in 1853 cancer patients 

      Solheim, Tora Skeidsvoll; Fayers, Peter; Fladvad, Torill; Tan, Ben; Skorpen, Frank; Fearon, Kenneth C.; Baracos, Vickie; Klepstad, Pål; Strasser, Florian; Kaasa, Stein (Journal article; Peer reviewed, 2012)
      Background Appetite loss has a major impact on cancer patients. It is exceedingly prevalent, is a prognostic indicator and is associated with inferior quality of life. Cachexia is a multi‐factorial syndrome defined by a ...

    • Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series 

      McDonald, James; Sayers, Judith; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Baracos, Vickie; Brown, Leo; Bye, Asta; Dajani, Olav; Dolan, Ross; Fallon, Marie T.; Fraser, Eilidh; Griel, Christine; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jamal-Hanjani, Mariam; Jakobsen, Gunnhild; Kaasa, Stein; McMillan, Donald; Maddocks, Matthew; Philips, Iain; Ottestad, Inger; Reid, Kieran F.; Sousa, Mariana S.; Simpson, Melanie Rae; Vagnildhaug, Ola Magne; Skipworth, Richard J. E.; Solheim, Tora S; Laird, Barry J (Peer reviewed; Journal article, 2023)
      In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures. However, ...

    • Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series 

      Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Coats, Andrew J.S.; Dajani, Olav; Dolan, Ross D.; Fallon, Marie T.; Greil, Christine; Grzyb, Alexandra; Kaasa, Stein; Koteng, Lisa Heide; May, Anne M.; McDonald, James; Ottestad, Inger; Philips, Iain; Roeland, Eric J.; Sayers, Judith; Simpson, Melanie Rae; Skipworth, Richard J.E.; Solheim, Tora S; Sousa, Mariana S.; Vagnildhaug, Ola Magne; Laird, Barry J.A. (Journal article; Peer reviewed, 2024)
      The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing, and perceptions of care, represent important measures of efficacy. ...